This inventor holds 1 USPTO granted patent. Top assignees: Tel Aviv University, The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center. Active years: 2013.
Company Filing History:
1 out of 840 
1 out of 60 Years Active: 2013
Title: Rahamim Ben-Yosef: Innovator in Immunotoxin Production
Introduction
Rahamim Ben-Yosef is a notable inventor based in Mevaseret-Zion, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of immunotoxins. His work focuses on creating targeted therapies that can effectively kill specific cells, which has important implications for medical treatments.
Latest Patents
Ben-Yosef holds a patent for a recombinant fusion protein and polynucleotide construct for immunotoxin production. The patent describes a polynucleotide construct encoding a fusion protein that consists of a domain binding the immunoglobulin Fc region, genetically fused to a truncated form of exotoxin A (PE). Specifically, the invention discloses the fusion protein ZZ-PE38 and provides immunotoxins formed from complexes of the fusion protein with antibodies for targeted cell killing. This innovation represents a significant advancement in the field of targeted cancer therapies.
Career Highlights
Throughout his career, Rahamim Ben-Yosef has worked with prestigious institutions, including Tel Aviv University and the Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Itai Benhar and Akiva Vexler. Their collaborative efforts have further enhanced the impact of Ben-Yosef's work in immunotoxin production.
Conclusion
Rahamim Ben-Yosef is a distinguished inventor whose work in immunotoxin production has the potential to revolutionize targeted therapies in medicine. His innovative approaches and collaborations with esteemed institutions highlight his commitment to advancing biotechnology.